China looks good for growth of Allergan's Botox and medical aesthetics
This article was originally published in Scrip
Appearance-conscious China has already become the world's third-largest market for plastic surgery, closing the gap on Brazil and the US, and is now an attractive market for companies like medical aesthetics specialist, Allergan, and its portfolio of cosmetically oriented pharmaceuticals including its wrinkle treatment Botox.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.